Notably, in 2019, the USFDA (and the EMA) approved this agent for the treatment of previously treated FL and marginal zone lymphoma (MZL) in combination with rituximab, based on the results of two phase III clinical trials, while in 2020, the combination of lenalidomide with the cytolytic CD19 targeting monoclonal antibody tafasitamab received accelerated approval for the treatment of R/R diffuse large B cell lymphoma (DLBCL) patients [17,18,19,20,21]. The gene discussed is CD19; the disease is marginal zone lymphoma.